MINNEAPOLIS, Nov. 27 /PRNewswire-FirstCall/ -- Uroplasty, Inc. announced today that Steve Bowers has accepted the newly-created position of National Business Development Manager - Pelvic Floor. Steve brings a wealth of pelvic floor experience and surgeon relationships from his previous positions in sales and sales management with Influence, American Medical Systems, Endocare and Novasys Medical.
Larry Heinemann, Vice President of Sales and Marketing, commented, “Having Steve in this role will allow Uroplasty to establish presence as a leader and innovator in the fast-growing and ever-changing U.S. sling and pelvic floor market. Steve will provide Uroplasty support for the I-Stop(TM) sling product with special emphasis on developing expanded sling indications and future products for the treatment of pelvic floor disorders.”
As the female sling market evolves from hospital-based to minimally- invasive office-based procedures, Uroplasty plans to offer products to meet these market changes. Additionally, Uroplasty intends to develop product offerings to meet the challenging disease state of male incontinence. Steve’s relationship with key surgeons will provide valuable collaboration for the development and market introduction of new sling options and office-based pelvic floor procedures. Steve Bowers summarized his role by saying, “I believe that the pelvic floor arena is a dynamic and rapidly changing marketplace. I am excited to work with the Uroplasty team to bring unique and innovative products to the surgeons that treat patients with incontinence and pelvic floor disorders.”
Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom, is a medical device company that develops, manufactures and markets innovative, proprietary products for the treatment of voiding dysfunctions. Uroplasty’s minimally invasive products treat urinary incontinence and overactive bladder symptoms. We believe that our company is uniquely positioned because we offer a broad and diverse set of products to address the various preferences of doctors and patients, as well as the quality of life issues presented by voiding dysfunctions.
Uroplasty currently offers three medical devices for the treatment of incontinence and overactive bladder symptoms. Uroplasty’s products include:
-- Macroplastique(R), a minimally invasive, implantable soft tissue bulking agent for the treatment of stress urinary incontinence. When Macroplastique is injected into tissue around the urethra, it stabilizes and “bulks” tissues close to the urethra, thereby providing the surrounding muscles with increased capability to control the release of urine. -- I-Stop(TM), a minimally invasive biocompatible, polypropylene, tension- free sling for the treatment of female urinary incontinence. The I- Stop sling can correct stress urinary incontinence by providing tension-free hammock-type support for the urethra to prevent its downward movement and the associated leakage of urine. -- The Urgent(R) PC neuromodulation system, a minimally invasive device designed for office-based treatment of overactive bladder symptoms of urge incontinence, urinary urgency and urinary frequency. This product uses percutaneous tibial nerve stimulation to deliver an electrical pulse that travels to the sacral nerve plexus, a control center for bladder function.
The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for certain forward-looking statements. This press release contains forward-looking statements, which reflect our views regarding future events and financial performance. These forward-looking statements are subject to certain risks and uncertainties, including those identified below, which could cause actual results to differ materially from historical results or those anticipated. The words “aim,” “believe,” “expect,” “anticipate,” “intend,” “estimate” and other expressions, which indicate future events and trends, identify forward-looking statements. Actual future results and trends may differ materially from historical results or those anticipated depending upon a variety of factors, including, but not limited to: the effect of government regulation, including when and if we receive approval for marketing products in the United States; the impact of international currency fluctuations on our cash flows and operating results; the impact of technological innovation and competition; acceptance of our products by physicians and patients, our historical reliance on a single product for most of our current sales; our ability to commercialize our recently licensed product lines; our intellectual property and the ability to prevent competitors from infringing our rights; the ability to receive third party reimbursement for our products; the results of clinical trials; our continued losses and the possible need to raise additional capital in the future; our ability to manage our international operations; our ability to hire and retain key technical and sales personnel; our dependence on key suppliers; future changes in applicable accounting rules; and volatility in our stock price. We cannot assure that we can develop expanded sling indications and future products for the treatment of pelvic floor disorders or establish presence as a leader and innovator in the U.S. sling and pelvic floor market.
FOR FURTHER INFORMATION: visit Uroplasty’s web page at http://www.uroplasty.com or contact Mr. Kaysen.
UROPLASTY, INC. David B. Kaysen, President / CEO 5420 Feltl Road Minnetonka, Minnesota 55343 Tel: 952.426.6140 Fax: 952.426.6199 E-mail: dave.kaysen@uroplasty.com
Uroplasty, Inc.
CONTACT: David B. Kaysen, President - CEO of Uroplasty, Inc.,+1-952-426-6140, Fax: +1-952-426-6199, dave.kaysen@uroplasty.com
Web site: http://www.uroplasty.com/
